ICU patients may need custom doses of common antifungal

NCT ID NCT02164890

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how the antifungal drug micafungin is processed in the bodies of 60 critically ill ICU patients with invasive candidiasis. Researchers took multiple blood samples to measure drug levels and understand why some patients might not get enough medicine. The goal is to improve dosing for this vulnerable group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

micafungin

What this could lead to

If successful, this could help doctors tailor micafungin doses for ICU patients, potentially improving treatment success.

What could go wrong

This is a small, completed pharmacokinetic study, not a treatment trial. It may not lead to new dosing guidelines or directly improve patient outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INVASIVE CANDIDIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

candidiasis, invasive disseminated candidiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU de Montpellier

    Montpellier, 34295, France